Navigation Links
Epstein-Barr Virus Antibody Panel II

ProductsEpstein-Barr Virus Antibody Panel II
Company ARUP Laboratories
Item Epstein-Barr Virus Antibody Panel II
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Epstein-Barr Virus (EBV) Early Antigen IFA
2. Epstein-Barr Nuclear Antigen (EBNA) ACIF (Anti-Complement Immunofluorescence)
3. Epstein-Barr Virus (EBV) VCA IgM Recombinant IFA (RIFA)
4. Epstein-Barr Virus (EBV) VCA IFA IgG
5. Epstein-Barr virus (EBV) ELISA
6. Epstein-Barr Virus EBNA-1 IgG II
7. Epstein-Barr Virus EBV-VCA IgG II
8. Epstein-Barr Virus EBV-EA IgG II
9. Epstein-Barr Virus EBV-VCA IgM II
10. Epstein-Barr Virus (EBV) Probe, Paraffin
11. Epstein-Barr Virus Antibody Panel I
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products:
(Date:12/3/2008)...ific Gamma Imaging (BSGI) has,equivalent sensitiv...ents with,inconclusive findings after mammography..., according to findings presented today at the ann...America (RSNA). BSGI is a molecular breast,imagin...phy that can identify,lesions independent of tiss...
(Date:12/3/2008)...irstCall/ -- MAP,Pharmaceuticals, Inc. (Nasdaq: ...rticipate in a panel discussion titled "Adapting S... the 2008 RBC Capital Markets Healthcare Conferenc...T) in New York City. , A live webcast of th...or,Relations section of MAP Pharmaceuticals, webs...
(Date:12/3/2008)...thinner imported from China , , WEDNESDA...e deadly contamination of the blood thinner hepari...de chemical that was added to batches of the drug ..., The crisis, which began last November, resulted... in the United States. The Chinese heparin, contam...
(Date:12/3/2008)...The gold coin tradition continues for The Salvatio...d into the red kettles, with the first coin appear...$50 coin was wrapped in a $2 bill and deposited in... in Norridge. , , Since the first gold coin...ation Army has seen gold coins of every type and d...
Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:Report Confirms Source of Contaminated Heparin 2Health News:Report Confirms Source of Contaminated Heparin 3
...ding to a new study from Columbia University rese...vement disorder, essential tremor (ET),// are more...healthy counterparts. Essential tremor is a disord...ieve it may be neurodegenerative in nature. The co...
...ding to a new study in the American Journal of Cli... play an important role in preventing the build up...vascular disease.// Research has shown antioxidant...ation of plaque in the arteries. However, most stu...
...ding to a notice distributed by the agency, the US...nited Therapeutics Corp.'s pulmonary arterial hype...A spokesperson for the FDA told Reuters Health tha... pulmonary arterial hypertension. The FDA approved...
...tists have ruled out a possible connection to auti...l Journal shows children with autism are no more l...stinal problems as infants. // Study investigators...children with autism and compared them to children...
Other Medicine News:
(Date:12/1/2008)...Dec. 2 New research has...lice computed tomography (CT) scanner in an emerge...stroke victims who receive a potentially life-savi...orth Shore Medical Center (NSMC)-Salem Hospital in...al meeting of the Radiological Society of North Am...
(Date:12/1/2008)..., Dec. 1 S*BIO Pte Ltd today annou...of SB1518, a potent and orally-active JAK2 inhibit...tients with chronic idiopathic myelofibrosis (CIMF...he safety and tolerability of SB1518 in patients w...s. The Phase 1 part of the study will assess the ...
(Date:12/1/2008)...tinence is still the best policy , , ROCHE...ew study from Mayo Clinic finds the use of the dru...olic hepatitis, an acute inflammation of the liver...esults of the study are published in the December ...rnal.org/ ). , , VIDEO ALERT: Additional a...
(Date:12/1/2008)...Dec. 1 GeoVax Labs, Inc....technology company developing,human vaccines for ...irus) and,other infectious agents, announced toda...rials will take place in twelve sites across North... collaboration with The National Institutes of,He...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3COX 2 expression is marker for cancer development in some benign breast biopsies 14088 1COX 2 expression is marker for cancer development in some benign breast biopsies 14088 2COX 2 expression is marker for cancer development in some benign breast biopsies 14088 3COX 2 expression is marker for cancer development in some benign breast biopsies 14088 4Mettler Toledo International Inc Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference 14086 1Zimmer Holdings to Present at Upcoming Investor Conferences 14084 1First early detection blood test for Parkinsons shows promise 14082 1First early detection blood test for Parkinsons shows promise 14082 2First early detection blood test for Parkinsons shows promise 14082 3
...S--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechn...tive Phase I and Phase,II data on the Company,s pr...cetate) were presented at the European Society for...ently taking place,in Lugano, Switzerland. The dat...ons on Sunday, July 8, as part of the session for,...
...GA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YM,...fies, develops,and commercializes differentiated p...at a study presented by investigators from Kinki,U...at the 11th,meeting of The Japanese Association fo...5-6, 2007 demonstrated the increased,radiosensitiv...
Other Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 2YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 3YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 4